The course is comprised of eight compulsory taught modules, followed by the Oxford Residential Week and the Dissertation.
In the September before the course start in October, you will have access to a "Module zero".
The aim of Module zero is to ensure students have a basic knowledge of cell biology and genetics which they will need before starting the course. It is not compulsory and will be there to strengthen their knowledge of core scientific concepts and will set students up ready for Module 1 and future modules.
The human genome and its variation; genome architecture; epigenetic modification; DNA damage and repair; cancer genomics; subclonality and mosaicism; cancer predisposition
Genomic technologies and techniques to interrogate genomic variation; application in RNA sequencing; metabolomics and proteomics; bioinformatic analysis; evaluating pathogenicity of variants
State-of-the-art diagnostics; biomarker properties and their clinical use; quality control; regulation; clinical interpretation
Processing and analysis of raw sequence data; interrogating major data sources; integrating results with clinical data; practical experience of the Genomics England bioinformatics pipeline; essential computational skills
Clinical trial design; genomic basis of drug efficacy and drug reaction; using genomics for targeted drug development; pharmacodynamics, resistance, and rational combinations; use of imaging and circulating biomarkers; regulatory aspects of drug development
Ethical principles in precision medicine; clinical and research ethics; balance of ethical principles with respect to individuals and society; ethics in the context of complexity and uncertainty; economic models in genomic medicine; justification of economics-based decisions
Tumour classification and digital pathology; sample requirements for multi-omics; genomic basis of cancer pre-disposition; imaging technologies; regulatory frameworks, clinical and scientific guidelines; global trends; early detection; role of artificial intelligence
Cancer immunotherapy; tumour-associated antigens; the immune microenvironment; oncolytic viruses and the role of the microbiome; checkpoint inhibitors; immune response in cancer patients; adaptive T-cell therapy; bioinformatics in tumour immunology
This course is reviewed annually and subject to minor changes in response to feedback and evaluation.